In case you missed it, the Institute for Clinical and Economic Review (ICER) is seeking suggestions to improve its value assessment framework prior to its re-release in 2017. For the past two years, ICER has been issuing assessment reports that raise significant concerns about the impact on patient access to medicines and continued medical progress. In response, ICER has received significant feedback from stakeholders across the health care spectrum.
World Hepatitis Day is a unique opportunity to take stock of the recent advancements in new treatments and cures to combat versions of hepatitis. Founded by the World Hepatitis Alliance, World Hepatitis Day brings awareness to the five hepatitis viruses that cause inflammation of the liver. This year’s theme for the global campaign is “Elimination.” With hepatitis being the leading cause of cirrhosis and liver cancer, the disease is the most common reason for a liver transplant in the United States, according to the Centers for Disease Control and Prevention.
The U.S. Food and Drug Administration (FDA) recently released its performance goals letter for the sixth installment of the Prescription Drug User Fee Act (PDUFA). The letter comes after months of technical negotiations between the agency and biopharmaceutical companies, and parallel meetings with patients’ advocacy groups, academia and other stakeholders.
This blog post is authored by Jeffrey Francer (PhRMA) and Deborah Shelton (BIO).
We are in an era of data-driven medicine. Patients, caregivers, health care professionals and insurers want more information about the safety, effectiveness and value of treatments – and rightly so. But federal regulations governing information-sharing about medicines have not kept up with this new reality.
For the past 50 years, the PhRMA Foundation has had the opportunity to support young scientists across numerous disciplines through grants and fellowships. In looking back through the years, and 2015 in particular, we asked past award recipients about the support they received. Here’s what some of them had to say:
As July comes to a close this week, there’s one big birthday left to celebrate – the anniversary of Medicare! On July 30, 1965, Medicare was signed into law by President Lyndon B. Johnson. This week, as we celebrate 51 years of Medicare, we wanted to highlight some of our Medicare resources.
When you think about vaccines, you may not think about the need for them later in life, but vaccines for older Americans are a critical component of maintaining health as you age. According to the Centers for Disease Control and Prevention, our immune systems weaken over time, which puts older Americans at higher risk for certain diseases. Important vaccines for older Americans include the flu, tetanus, hepatitis A and B, pertussis (whooping cough), pneumococcal, meningococcal, shingles and more.
An informed consumer is an engaged and empowered patient. With the right information, consumers are well equipped to be active participants in making decisions about their health care. But it isn’t always that simple. Consumers often face barriers when it comes to finding information about their insurance benefits and out-of-pocket costs. By removing these barriers, we can engage and empower patients to make better-informed decisions about their health care. Here are four ways to do this:
New National Health Expenditure (NHE) projections released today by the Centers for Medicare & Medicaid Services reaffirm how our nation’s competitive marketplace for medicines controls costs while supporting the development of new treatments and cures for patients.
In the age of personalized medicine, biomarkers are emerging as important tools in drug development. A biomarker is a measure or physical sign that can be used to determine how the body is functioning. This can help researchers develop more individualized treatments, provide an early warning sign for certain health risks and accelerate the availability of new medicines for patients.